Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ovarian cancer.

Nicoletta Colombo1, Toon Van Gorp, Gabriella Parma

  • 1European Institute of Oncology, Division of Gynecology, Via Ripamonti 435, Milan, Italy. nicoletta.colombo@ieo.it

Critical Reviews in Oncology/Hematology
|October 5, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TLD-1, a Novel Liposomal Doxorubicin, in Patients with Solid Tumors: Comparative Pharmacokinetics and Final Results of a Multicenter Phase 1 Study (SAKK 65/16).

Clinical pharmacokinetics·2025
Same author

A systematic review of phase I trials in patients with ovarian cancer.

Cancer treatment reviews·2025
Same author

A Retrospective Assessment of Computed Tomography-Based Body Composition and Toxicity in Ovarian Cancer Patients Treated with PARP Inhibitors.

Cancers·2025
Same author

Can we learn from failures? A systematic review of phase III trials in platinum-resistant ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2025
Same author

European Cancer Organisation Essential Requirements for Quality Cancer Care for ovarian cancer: Focus on the multidisciplinary team.

Tumori·2024
Same author

The active involvement of patients in oncology research.

Cancer treatment reviews·2024
Same journal

Liquid biopsy for early cancer detection in hereditary cancer syndromes: current evidence.

Critical reviews in oncology/hematology·2026
Same journal

Estrobolome and the Endocrine-Microbiome Axis in Breast and Endometrial Carcinogenesis.

Critical reviews in oncology/hematology·2026
Same journal

Remodeling the immune microenvironment: Engineering IL-2 variants to overcome clinical bottlenecks in PD-1 inhibitor plus chemotherapy.

Critical reviews in oncology/hematology·2026
Same journal

Neoadjuvant immunotherapy in melanoma: From pathologic response to response-adapted management.

Critical reviews in oncology/hematology·2026
Same journal

DNA polymerase epsilon catalytic subunit (POLE) in cancer: Implications for tumor biology and therapeutic strategies - A comprehensive review.

Critical reviews in oncology/hematology·2026
Same journal

Long non-coding RNAs in triple-negative breast cancer: emerging drivers of tumor biology, prognosis, and drug resistance.

Critical reviews in oncology/hematology·2026
See all related articles

Ovarian cancer diagnosis often occurs at advanced stages, significantly impacting survival rates. Comprehensive surgical staging and tailored chemotherapy, including platinum-based regimens, are crucial for effective ovarian cancer management and improved patient outcomes.

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology

Background:

  • Ovarian cancer is a leading cause of gynecologic cancer death, with most women diagnosed at advanced stages.
  • Early-stage diagnosis offers high survival rates (80-90%), contrasting sharply with advanced-stage survival (25%).

Purpose of the Study:

  • To outline current management strategies for ovarian cancer based on disease stage.
  • To emphasize the importance of surgical staging and chemotherapy in treatment protocols.

Main Methods:

  • Review of standard treatment guidelines for early and advanced ovarian cancer.
  • Discussion of surgical staging, adjuvant chemotherapy, primary cytoreductive surgery, and salvage therapies.

Main Results:

  • Optimal surgical staging and platinum-based chemotherapy are recommended for high-risk early-stage tumors.

Related Experiment Videos

  • Primary cytoreductive surgery followed by platinum-paclitaxel chemotherapy is standard for advanced disease.
  • Salvage therapy selection depends on recurrence patterns and prior treatment, with platinum-based regimens for sensitive relapse.

    • Conclusions:

    • Comprehensive surgical staging is essential for all ovarian cancer patients.
    • Treatment strategies must be individualized based on stage, risk, and recurrence.
    • While platinum-based chemotherapy is effective, outcomes for platinum-refractory disease remain poor.